Management of anticoagulation in cirrhosis is challenging because of the concomitant risk of both thromboembolism and bleeding complications. Randomized controlled studies are lacking. Direct oral anticoagulants seem to be the most manageable option. However, for patients with Child C cirrhosis, the only safer anticoagulant strategy, currently, is low-molecular-weight heparin.

中文翻译：

---

肝硬化中的抗凝剂：主要关注点


肝硬化患者的抗凝管理具有挑战性，因为伴随血栓栓塞和出血并发症的风险。缺乏随机对照研究。直接口服抗凝剂似乎是最容易控制的选择。然而，对于儿童 C 肝硬化患者，目前唯一更安全的抗凝策略是低分子肝素。